Opendata, web and dolomites

BERMES SIGNED

A Novel BERberine derivative for Malignant MESothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BERMES project word cloud

Explore the words cloud of the BERMES project. It provides you a very rough idea of what is the project "BERMES" about.

malignant    incidences    medicine    therapy    lungs    rare    internal    undertaken    emergence    last    drug    efficacy    treatment    innovative    good    trial    testis    resistant    exposure    diagnosis    drugs    44    manufacture    shown    data    pharmacokinetic    banned    completion    covers    nax035    toxicity    survival    safety    oral    union    definitely    derivative    organization    first    mesothelium    cisplatin    mm    heart    thin    right    pemetrexed    aggressive    chemoresistance    standard    valley    arising    death    mesothelioma    despite    administered    exhibited    bermes    world    solved    january    trials    pulling    agent    2020    gap    combination    peritoneal    close    authorization    2005    latency    limited    translational    orphan    disease    cavity    designation    health    forms    clinical    none    asbestos    burden    regulatory    period    deal    improvement    organs    peak    malignancy    layer    preliminary    antitumour    worldwide    tissue    line    berberine    obtaining    agency   

Project "BERMES" data sheet

The following table provides information about the project.

Coordinator
APPLIED RESEARCH USING OMIC SCIENCES SL 

Organization address
address: CALLE VICTOR PRADERA 45
city: CORNELLA
postcode: 8940
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙550˙942 €
 EC max contribution 1˙085˙659 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    APPLIED RESEARCH USING OMIC SCIENCES SL ES (CORNELLA) coordinator 1˙085˙659.00

Map

 Project objective

Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis. The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020. The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance. NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BERMES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BERMES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More